Ocular Therapeutix, Inc. (OCUL) financial statements and ratios from SEC XBRL: revenue $0.1B (TTM), net margin -511.9%, revenue growth -18.5% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $51.95M |
| Revenue (TTM) | $0.1B |
| Net Margin | -511.9% |
| Operating Margin (TTM) | -658.5% |
| Revenue Growth (YoY) | -18.5% |
| EPS Growth (YoY) | 16.4% |
| FCF Growth (YoY) | 59.5% |
| Price / Book | 4.67 |
| Price / Sales | 49.03 |
| FCF Yield | -18.2% |
| Altman Z-Score | 7.45 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
OCUL overview · OCUL earnings · OCUL KPIs · OCUL documents · OCUL ownership · OCUL peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.